Semaglutide Research Guide

Semaglutide is a long-acting GLP-1 receptor agonist used in type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Understanding its pharmacokinetics explains both its efficacy and its side-effect profile.

Pharmacokinetics at a glance

Semaglutide Injection (Ozempic/Wegovy) has a half-life of roughly 6.5 days, which permits once-weekly injection. Steady state is reached after about 4–5 weeks, and peak concentration occurs around 1–2 days post-dose.

Why titrate?

The classic titration schedule (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) exists primarily to manage gastrointestinal side effects. Because the drug accumulates over a month, starting at full dose produces severe nausea and vomiting in many patients.

Injectable vs. oral

The oral formulation (Rybelsus) has dramatically lower bioavailability (~1%) and a much shorter half-life, requiring daily fasting dosing. Our plotter lets you compare the two formulations directly.

PMC: semaglutide pharmacokinetics ^[src]

Reading your curve

Plot a titration protocol and observe how trough levels climb week over week. The “steady-state trough” is what drives both efficacy and the plateau many patients report after several months.